---
category: news
title: "BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of ..."
excerpt: "Primary safety endpoint achieved in first study of BXCL501 dosed twice-daily over seven days RELEASE results demonstrated numerically improved retention rates in multiple BXCL501 dose cohorts Data from multiple dosing regimen in RELEASE supports investigation across additional indications and treatment settings NEW HAVEN,"
publishedDateTime: 2021-03-31T20:02:00Z
originalUrl: "https://apnews.com/press-release/globe-newswire/business-products-and-services-government-regulations-coronavirus-pandemic-product-approvals-a07d038804a69569e2f1c2c27eb4f232"
webUrl: "https://apnews.com/press-release/globe-newswire/business-products-and-services-government-regulations-coronavirus-pandemic-product-approvals-a07d038804a69569e2f1c2c27eb4f232"
type: article
quality: 12
heat: 12
published: false

provider:
  name: Associated Press
  domain: apnews.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://apnews.com/images/PaidContent3.png"
    width: 700
    height: 450
    isCached: true

secured: "dyCGHUYWEoRYVe2RIYA4YzwPzfYawYS4EyUTQScYhaFLl8aEaAenyyS1fVYNDzVRA32gWqta8Efd95Pp3qTeKVkSAVD3AkqY0yQIrgCBcjWY/W0gvNy5mZ1P3fRH6qGqqME2ua3jrOebkFPQtrzgph0OgvfBbRvc9mzpGxP6u3D3Npwi6W60bGW2Fuk9H5SEj0JuTwNdQ+y8U3lUxlavW88i/mVnQsy0aSp0gt0leLgAkrd5/yNXLkWp1MuymyRCT9Pj3C2WJWedkNtwrwO69lPO5zjFbXiB0WcHytubyufNjAsXctySWc4R40FtlKTgTCWFInMQBgcAwm8r9YbtYETZVQZp2cNRZursr3uyD7U=;88txBoQKSwv6Q6MMaiYnpA=="
---

